HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies

A significant shift in the ownership structure of pharmaceutical player Corona Remedies Limited occurred on June 17, 2026, as major institutional investors stepped in to acquire a substantial stake. This massive block deal marks a key movement in the healthcare sector, involving some of the world’s most prominent asset management firms.

Massive Divestment by Sepia Investments and Anchor Partners

The block deal was headlined by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. Executed at a price of ₹1,730 per share, the transaction by Sepia alone amounted to approximately ₹748.9 crore. Adding to the sell-side momentum, Anchor Partners also divested its holdings, selling 1,61,861 shares at the same price point, worth roughly ₹28 crore.

In total, these two sellers successfully exited or reduced their positions by offloading shares worth approximately ₹776.9 crore in the pharmaceutical company, signaling a major liquidity event in the stock.

HDFC Mutual Fund Dominates the Buy Side

While the sell-side was concentrated among two entities, the buy-side saw intense participation from twelve different institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, single-handedly absorbing more than half of the total deal value. HDFC MF acquired 24,50,000 shares, an investment totaling roughly ₹423.9 crore.

Other heavyweight domestic and international players also secured significant positions:

• Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
• Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares valued at ₹78 crore.
• Invesco Mutual Fund: Acquired 2,89,017 shares for approximately ₹50 crore.
• Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, a volume that exactly matched the quantity sold by Anchor Partners.

Global Institutional Interest in Corona Remedies

The deal also highlights growing interest from global sovereign wealth funds and specialized emerging market funds. The Abu Dhabi Investment Authority (ADIA) participated in the deal, purchasing 39,130 shares worth approximately ₹6.8 crore.

此外，WhiteOak 集团表现出了极强的信心，其中 Ashoka WhiteOak Emerging Markets Equity Fund 买入了 148,686 股（2.57 亿卢比），WhiteOak Capital Mutual Fund 收购了 145,000 股（2.51 亿卢比）。其他参与者包括 Aberdeen Standard Sicav I、India Acorn ICAV 和 Factory Mutual Insurance Company，彰显了机构投资者在 1,730 卢比这一价格水平上对该公司广泛的信心。

核心要点

• 重大股权转让： Sepia Investments 和 Anchor Partners 通过大宗交易，合计减持了约 77.69 亿卢比的 Corona Remedies 股份。
• HDFC MF 作为主要买方： HDFC Mutual Fund 是主要的收购方，投资 42.39 亿卢比购买了 245 万股，占交易总额的 50% 以上。
• 广泛的机构兴趣： 该交易吸引了包括 ADIA 和 Aberdeen 等全球巨头以及印度主要共同基金在内的 12 家不同类型的投资者参与。